Alpha Teknova (NASDAQ:TKNO) CEO Purchases $55,900.00 in Stock

Alpha Teknova, Inc. (NASDAQ:TKNO) CEO Stephen Gunstream bought 26,000 shares of Alpha Teknova stock in a transaction dated Friday, March 6th. The stock was purchased at an average price of $2.15 per share, for a total transaction of $55,900.00. Following the purchase, the chief executive officer directly owned 269,497 shares in the company, valued at $579,418.55. This represents a 10.68% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Alpha Teknova Trading Up 0.5%

TKNO traded up $0.01 during mid-day trading on Monday, reaching $2.12. The stock had a trading volume of 133,305 shares, compared to its average volume of 262,362. The firm’s fifty day simple moving average is $2.90 and its two-hundred day simple moving average is $4.16. The stock has a market capitalization of $113.61 million, a P/E ratio of -6.42 and a beta of 0.39. Alpha Teknova, Inc. has a 52 week low of $1.91 and a 52 week high of $7.48. The company has a debt-to-equity ratio of 0.19, a quick ratio of 3.64 and a current ratio of 4.58.

Alpha Teknova (NASDAQ:TKNO) last posted its earnings results on Thursday, February 26th. The company reported ($0.09) earnings per share for the quarter, hitting the consensus estimate of ($0.09). Alpha Teknova had a negative net margin of 42.59% and a negative return on equity of 23.32%. The company had revenue of $9.98 million for the quarter, compared to analyst estimates of $9.62 million. On average, equities analysts predict that Alpha Teknova, Inc. will post -0.58 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on TKNO. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alpha Teknova in a research note on Wednesday, January 21st. Zacks Research raised Alpha Teknova to a “hold” rating in a research note on Wednesday, December 10th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $8.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Roubaix Capital LLC grew its holdings in shares of Alpha Teknova by 89.5% during the third quarter. Roubaix Capital LLC now owns 833,819 shares of the company’s stock valued at $5,161,000 after buying an additional 393,881 shares during the last quarter. Royce & Associates LP bought a new stake in Alpha Teknova in the fourth quarter worth about $1,116,000. Balyasny Asset Management L.P. grew its holdings in Alpha Teknova by 19.5% during the second quarter. Balyasny Asset Management L.P. now owns 1,000,484 shares of the company’s stock valued at $4,912,000 after purchasing an additional 163,526 shares during the period. Tradewinds LLC. bought a new position in shares of Alpha Teknova during the 3rd quarter worth $969,000. Finally, Massar Capital Management LP raised its position in shares of Alpha Teknova by 185.7% in the second quarter. Massar Capital Management LP now owns 200,000 shares of the company’s stock valued at $982,000 after purchasing an additional 130,000 shares during the period. 13.81% of the stock is owned by institutional investors.

Alpha Teknova Company Profile

Alpha Teknova, Inc (NASDAQ: TKNO) is a life science tools and reagents company that develops, manufactures and distributes proprietary products to support research, drug discovery and biomanufacturing. Its offerings target academic institutions, pharmaceutical and biotechnology firms, and diagnostic developers, with a focus on high-purity reagents and optimized workflows designed to accelerate molecular biology and protein science applications.

The company’s portfolio includes molecular biology reagents, cell culture buffers, in vitro translation kits, custom recombinant proteins, high-throughput screening buffers and other specialized formulations.